Stephen Gardner to Reverse Transcriptase Inhibitors
This is a "connection" page, showing publications Stephen Gardner has written about Reverse Transcriptase Inhibitors.
Connection Strength
0.385
-
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005 Feb; 42(2):173-9.
Score: 0.062
-
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90.
Score: 0.058
-
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003 Apr; 37(4):748-55.
Score: 0.055
-
Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17.
Score: 0.054
-
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan; 9(1):49-56.
Score: 0.054
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94.
Score: 0.052
-
Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002 May 30; 346(22):1706-13.
Score: 0.052